Bone-targeted agents: preventing skeletal complications in prostate cancer.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Urologic clinics of North America

• Publication date

  2012-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ucl.2012.07.009PMID 23084529PMCID PMC3721069
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.

  2012cited by this paper
• Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases.

  2012cited by this paper
• Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

  2011cited by this paper
• Treatment and prevention of bone complications from prostate cancer.

  2011cited by this paper
• Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer.

  2010cited by this paper
• Contemporary therapeutic approaches targeting bone complications in prostate cancer.

  2010cited by this paper
• Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.

  2009cited by this paper
• Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

  2009cited by this paper
• Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

  2009cited by this paper
• Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials

  2009cited by this paper
• FRAX™ and the assessment of fracture probability in men and women from the UK

  2008cited by this paper
• Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.

  2008cited by this paper
• National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist.

  2008cited by this paper
• Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study.

  2008cited by this paper
• Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.

  2008cited by this paper
• Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

  2007cited by this paper
• Effect of Once-Weekly Oral Alendronate on Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

  2007cited by this paper
• Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873).

  2007cited by this paper
• Osteoporosis in men.

  2007cited by this paper
• Biology of RANK, RANKL, and osteoprotegerin

  2007cited by this paper
• Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer.

  2006cited by this paper
• Denosumab in postmenopausal women with low bone mineral density.

  2006cited by this paper
• Bone fragility in men - where are we?

  2006cited by this paper
• Osteoblasts in prostate cancer metastasis to bone

  2005cited by this paper
• Risk of fracture after androgen deprivation for prostate cancer.

  2005cited by this paper
• Androgen deprivation therapy for prostate cancer.

  2005cited by this paper
• Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.

  2005cited by this paper
• Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.

  2005cited by this paper
• Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

  2004cited by this paper
• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

  2004cited by this paper
• Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.

  2004cited by this paper
• Neridronate Prevents Bone Loss in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer

  2004cited by this paper
• Mechanisms of bone metastasis.

  2004cited by this paper
• Mechanisms of bone metastasis.

  2004cited by this paper
• Contribution of Androgen Deprivation Therapy to Elevated Osteoclast Activity in Men with Metastatic Prostate Cancer

  2004cited by this paper
• Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer.

  2004cited by this paper
• Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.

  2004cited by this paper
• Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial.

  2004cited by this paper
• Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group.

  2003cited by this paper
• Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.

  2003cited by this paper
• Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.

  2003cited by this paper
• Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.

  2003cited by this paper
• Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

  2003cited by this paper
• Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma

  2003cited by this paper
• A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).

  2003cited by this paper
• Strontium89 Chloride versus Palliative Local Field Radiotherapy in Patients with Hormonal Escaped Prostate Cancer: A Phase III Study of the European Organisation for Research and Treatment of Cancer Genitourinary Group

  2003cited by this paper
• Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.

  2002cited by this paper
• A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

  2002cited by this paper
• Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs.

  2002cited by this paper
• Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities

  2002cited by this paper
• The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade

  2001cited by this paper
• Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.

  2001cited by this paper
• Progressive osteoporosis during androgen deprivation therapy for prostate cancer.

  2000cited by this paper
• Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline.

  2000cited by this paper
• Acute myelogenous leukemia after exposure to strontium‐89 for the treatment of adenocarcinoma of the prostate

  2000cited by this paper
• Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma.

  1999cited by this paper
• Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.

  1999cited by this paper
• Osteoporosis in men.

  1999cited by this paper
• Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial.

  1998cited by this paper
• Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen.

  1998cited by this paper
• Overview of bisphosphonates

  1997cited by this paper
• Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens.

  1997cited by this paper
• Endogenous Sex Steroids and Bone Mineral Density in Older Women and Men: The Rancho Bernardo Study

  1997cited by this paper
• Hip fracture in elderly men: prognostic factors and outcomes

  1997cited by this paper
• Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.

  1996cited by this paper
• Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.

  1996cited by this paper
• A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer.

  1994cited by this paper
• Positron emission tomographic measurement of bone marrow blood flow to the pelvis and lumbar vertebrae in young normal adults.

  1994cited by this paper
• Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.

  1993cited by this paper
• Osteoblast function and osteomalacia in metastatic prostate cancer.

  1993cited by this paper
• Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer.

  1992cited by this paper
• Morphometric evidence for bone resorption and replacement in prostate cancer.

  1991cited by this paper
• Evidence of estrogen receptors in normal human osteoblast-like cells

  1988cited by this paper
• Evidence of estrogen receptors in normal human osteoblast-like cells.

  1988cited by this paper
• Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose.

  1986cited by this paper
• 0163-769X/98/$03.00/0 Endocrine Reviews 19(1): 18–54 Copyright © 1998 by The Endocrine Society Printed in U.S.A. Cancer and Bone*

  year unknowncited by this paper
• The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Effects of Gonadal Steroid Suppression on Skeletal Sensitivity to Parathyroid Hormone in Men*

  year unknowncited by this paper

• Importance of the correct assessment of bone fractures in the clinical management of metastatic castration-resistant prostate cancer treated with radium-223: A case report.

  2019cites this paper
• Metastatic Prostate Cancer

  2018cites this paper
• Revisiting the role of bone‐modifying agents in the management of metastatic prostate cancer

  2018cites this paper
• The Effect of a Histone Deacetylase Inhibitor (AR‐42) on Canine Prostate Cancer Growth and Metastasis

  2017cites this paper
• Potential Implication of Paxillin in Cancer Establishment Within the Bone Environment.

  2017cites this paper
• Quality of Life Outcome Analysis of Robotic Radical Prostatectomy : A Single Center Experience

  2016cites this paper
• Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis

  2016cites this paper
• Bone Health in Prostate Cancer

  2016cites this paper
• Omentum and bone marrow: how adipocyte‐rich organs create tumour microenvironments conducive for metastatic progression

  2016cites this paper
• OPG‐Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice

  2015cites this paper
• Importance of bone assessment and prevention of osteoporotic fracture in patients with prostate cancer in the gonadotropic hormone analogues use.

  2015cites this paper
• Future of bisphosphonates and denosumab for men with advanced prostate cancer

  2014cites this paper
• Practical guide to the use of radium 223 dichloride.

  2014cites this paper
• Review of Animal Models of Prostate Cancer Bone Metastasis

  2014cites this paper
• Surgical emergencies in oncology.

  2014cites this paper
• Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone.

  2014cites this paper
• Bone Mineral Density in Prostate Cancer Patients with Drug Induced Hypogonadism

  2014influential citation
• Antineoplastic activity of zoledronic acid and denosumab.

  2013cites this paper
• Cancer Management and Research Dovepress Future of Bisphosphonates and Denosumab for Men with Advanced Prostate Cancer

  year unknowncites this paper